GENMARK DIAGNOSTICS INC's ticker is GNMK and the CUSIP is 372309104. A total of 98 filers reported holding GENMARK DIAGNOSTICS INC in Q1 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2021 | $1,673,000 | -29.3% | 70,000 | -56.8% | 0.02% | -34.4% |
Q4 2020 | $2,365,000 | -12.6% | 161,955 | -15.0% | 0.03% | -38.5% |
Q3 2020 | $2,707,000 | -17.0% | 190,623 | -14.0% | 0.05% | +18.2% |
Q2 2020 | $3,262,000 | +709.4% | 221,658 | +164.2% | 0.04% | +340.0% |
Q4 2019 | $403,000 | +194.2% | 83,900 | +272.9% | 0.01% | +150.0% |
Q3 2019 | $137,000 | -88.5% | 22,500 | -86.6% | 0.00% | -90.2% |
Q1 2019 | $1,187,000 | +62.8% | 167,400 | +11.6% | 0.04% | +46.4% |
Q4 2018 | $729,000 | -73.6% | 150,000 | -60.1% | 0.03% | -77.2% |
Q3 2018 | $2,763,000 | +56.5% | 376,000 | +35.9% | 0.12% | +28.1% |
Q2 2018 | $1,766,000 | +8.2% | 276,700 | -7.8% | 0.10% | -21.3% |
Q1 2018 | $1,632,000 | +160.7% | 300,000 | +100.0% | 0.12% | +139.2% |
Q4 2017 | $626,000 | -69.0% | 150,000 | -28.6% | 0.05% | -72.4% |
Q3 2017 | $2,022,000 | -58.5% | 210,000 | -49.0% | 0.18% | -63.1% |
Q2 2017 | $4,869,000 | +16.8% | 411,600 | +26.6% | 0.50% | +20.1% |
Q1 2017 | $4,167,000 | – | 325,000 | – | 0.42% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Camber Capital Management LP | 950,000 | $9,823,000 | 1.01% |
Curi RMB Capital, LLC | 939,265 | $9,720,000 | 0.74% |
KOPP INVESTMENT ADVISORS LLC | 96,384 | $997,000 | 0.39% |
Alyeska Investment Group, L.P. | 314,502 | $3,254,000 | 0.16% |
PFM Health Sciences, LP | 604,199 | $6,252,000 | 0.13% |
Spark Investment Management LLC | 47,000 | $485,000 | 0.13% |
ELLINGTON MANAGEMENT GROUP LLC | 61,700 | $638,000 | 0.12% |
PUTNAM INVESTMENTS LLC | 1,745,494 | $18,048,000 | 0.05% |
PointState Capital LP | 298,976 | $3,094,000 | 0.05% |
Partner Investment Management, L.P. | 20,717 | $214,000 | 0.05% |